Floatz logo

sph5030

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

Shanghai Pharmaceuticals Holding Co., LtdSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Biliary Tract or Colorectal Cancer With Her2-positive/Mutated cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

sph5030 is also rated in:

metastatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →
cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →